Skip to search.
 TSX Up 0.74% TSX Ventures Up 1.17%

Celgene Corporation (CELG)

-NasdaqGS
101.02 Down 0.44(0.43%) May 23, 4:00PM EDT
Prev Close:101.46
Open:101.31
Bid:99.47 x 100
Ask:105.60 x 700
1y Target Est:136.82
Beta:1.61363
Earnings Date:Jul 21 - Jul 25 (Est.)
Day's Range:100.80 - 102.25
52wk Range:92.98 - 140.72
Volume:2,756,537
Avg Vol (3m):4,798,960
Market Cap:78.25B
P/E (ttm):49.13
EPS (ttm):2.06
Div & Yield:N/A (N/A)
Quotes delayed, except where indicated otherwise. Currency in USD.

Comparison

Symbol% ChgMkt Cap
CELGDown 0.43%78.25B
JNJDown 0.43%308.51B

Key Statistics

Forward P/E (1 yr):14.43
P/S (ttm):8.11
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Dec-16) :5.67
Quarterly EPS Est (Jun-16) :1.38
Mean Recommendation*:1.8
PEG Ratio (5 yr expected):0.81

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell ly... View More
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback